- Home
- ADAM vs ATXS Comparison
ADAM vs ATXS Comparison
Compare ADAM & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAM | ATXS |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.9M | 732.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADAM | ATXS |
|---|---|---|
| Price | $8.76 | $12.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | $8.25 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 796.7K | 786.8K |
| Earning Date | 02-18-2026 | 03-10-2026 |
| Dividend Yield | ★ 10.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $216,781,000.00 | $706,000.00 |
| Revenue This Year | $11.01 | N/A |
| Revenue Next Year | $41.33 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.02 | $3.56 |
| 52 Week High | $8.76 | $13.29 |
Technical Indicators
Market Signals| Indicator | ADAM | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.24 |
| Support Level | N/A | $12.49 |
| Resistance Level | N/A | $12.86 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.00 | 6.29 |
Price Performance
Historical ComparisonAbout ADAM Adamas Trust Inc.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing and managing primarily mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit sensitive single-family and multi-family assets.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.